ASH
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Ashland Inc. is a global additives and specialty ingredients company serving consumer and industrial markets. Its reportable segments include Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences provides pharmaceutical excipients, controlled release polymers, and nutrition solutions using cellulosics and polyvinylpyrrolidones. Personal Care offers biofunctional actives, preservatives, and specialty polymers for skin, hair, oral, and household care. Specialty Additives supplies rheology modifiers, surfactants, and performance-enhancing additives for architectural coatings, construction, energy, and automotive sectors. The Intermediates segment produces 1,4-butanediol and n-methylpyrrolidone for engineering polymers and polyurethanes. The company serves customers across the Americas, Europe, the Middle East, Africa, and Asia Pacific.

Summarised from the company's own disclosures, fiscal year ended Nov 2025

Industry Specialty Chemicals Homepage ashland.com
Sector Basic Materials IR page investor.ashland.com
Tags
pharmaceutical excipients, personal care ingredients, coatings additives, construction chemicals, polyvinylpyrrolidones, cellulosics, 1 4-butanediol, rheology modifiers, preservatives, specialty polymers, Life Sciences, Personal Care, Specialty Additives, Intermediates, Zeta Fraction, plant small RNAs, n-methylpyrrolidone
Press page —

Metrics

Valuation  
Market cap $ 3.11B
Market cap (USD) $ 3.11B
P/E 38.81
PEG —
P/BV 1.66
P/S 1.69
P/OCF 9.28
P/FCF 12.44
Dividend yield —
Turnover / mcap —
Returns  
ROE -35.4%
ROI -25.7%
ROIC -17.7%
Profit margin -46.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 73.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score -58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 1.824B 2.113B 2.191B 2.391B 2.111B 2.326B 2.493B 3.743B 3.26B 4.948B 5.387B 0
Net profit -845M 169M 178M 927M 220M -508M 505M 114M 1M -29M 309M —
Free cash flow 36M 325M 124M 80M 361M 175M 74M 159M 56M 403M -176M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 47.91 86.97 81.68 94.97 89.12 70.92 77.05 83.86 65.39 115.95 108.75 —
Price performance 12m -0.45 0.06 -0.14 0.07 0.26 -0.08 -0.08 0.28 -0.44 0.07 -0 —

Filed figures

Figure Sep 2016 Sep 2017 Sep 2018 Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025
Balance sheet detail
Trade receivables (USD) 894M 612M 681M 481M 471M 369M 402M 338M 243M 242M
↳ YoY growth -7.0% -31.5% +11.3% -29.4% -2.1% -21.7% +8.9% -15.9% -28.1% -0.4%
↳ 5y CAGR -13.3% -16.2% -8.1% -13.1% -12.8% -12.5%
Borrowings, current (USD) 189M 235M 254M 166M 280M 374M 0.00 16M 0.00 0.00
Borrowings, non-current (USD) 3.06B 2.58B 2.28B 1.5B 1.57B 1.6B 1.27B 1.31B 1.35B 1.38B
Lease liabilities (USD) — — — 174M 147M 133M 113M 128M 119M 106M
Cash and deposits (USD) 1.19B 566M 294M 232M 454M 210M 646M 417M 300M 215M
Intangible assets (USD) 1.06B 1.32B 1.23B 1.09B 1.01B 1.1B 963M 886M 751M 563M
Right-of-use assets (USD) — — — 174M 137M 124M 107M 122M 114M 103M
Net debt (borrowings + leases - cash) (USD) 2.06B 2.25B 2.24B 1.44B 1.55B 1.89B 737M 1.04B 1.17B 1.28B
Cash flow detail
Operating cash flow (USD) 703M 255M 344M 228M 313M 466M 193M 294M 462M 134M
Purchases of property, plant and equipment (USD) -300M -199M -185M -154M -138M -105M -113M -170M -137M -98M
Change in receivables (cash effect) (USD) 55M -64M -70M 38M 7M 72M -23M 58M 96M -3M
Change in inventories (cash effect) (USD) 44M -23M -29M -4M 65M 41M -141M -7M 79M -28M
Change in payables (cash effect) (USD) -59M 60M 85M -79M -50M 3M 34M -112M 56M -63M
Dividends paid (cash effect) (USD) -97M -77M -60M -64M -66M -70M -70M -76M -78M -76M
Share buybacks (cash effect) (USD) -500M 0.00 — -200M — -450M -200M -300M -380M -100M
Interest paid (cash effect) (USD) -162M -132M -126M -124M -77M -62M -56M -53M -52M -54M
Income taxes paid (cash effect) (USD) -108M -79M -77M -67M -91M -1M -406M -63M -53M -33M
Share-based compensation (USD) 30M 20M 28M 21M 14M 15M 18M 22M 15M 14M
Operating cash flow before change in receivables (USD) 648M 319M 414M 190M 306M 394M 216M 236M 366M 137M
Free cash flow (OCF - PPE - intangibles) (USD) 403M 56M 159M 74M 175M 361M 80M 124M 325M 36M
Income detail
Research and development expense (USD) 100M 83M 85M 66M 64M 50M 55M 51M 55M 54M
↳ 5y CAGR -10.4% -10.3% -12.9% -7.9% -9.7% -3.6% -3.3%
Total comprehensive income (USD) -11M 120M 45M 420M -481M 231M 730M 244M 224M -798M
Comprehensive income to owners (USD) -12M 93M 45M 420M — — — — — —
Provision for credit losses (USD) — — — — — 0.00 0.00 0.00 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — — — — 0.0% 0.0% 0.0% 0.0% 0.0%
Reported Nov 21, 2016 Nov 20, 2017 Nov 19, 2018 Jan 29, 2020 Nov 23, 2020 Nov 17, 2023 Nov 17, 2023 Nov 17, 2023 Nov 18, 2024 Feb 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 3, 2026

PDF Version

  • Sales of $498 million, up four percent from the prior-year quarter

  • Loss from continuing operations of $17 million, or ($0.36) per diluted share

  • Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $52 million, or $1.12 per diluted share

  • Net loss of $16 million, or ($0.35) per diluted share

  • Sales volumes rose three percent from the prior-year quarter, led by growth in Life Sciences and Personal Care

  • Adjusted EBITDA of $121 million, up two percent from the prior-year quarter; strong growth in Life Sciences, Personal Care, and Intermediates was partially offset by lower earnings in Specialty Additives

  • Cash flows provided by operating activities of $90 million; Ongoing Free Cash Flow2 of $74 million

  • Issues outlook for full‑year fiscal 2027 sales of $1,905-$1,975 million and Adjusted EBITDA of $405-$435 million

WILMINGTON, Del., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the fourth quarter of fiscal year 2026, which ended September 30, 2026, together with its fiscal year 2026 results summary and full-year fiscal 2027 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.

“Ashland closed fiscal 2026 with strong commercial performance across our higher-growth Life Sciences and Personal Care businesses, as well as coatings and performance specialties within Specialty Additives, and improved profitability in Intermediates,” said Guillermo Novo, chair and chief executive officer, Ashland. “Life Sciences delivered four percent sales growth, and pharma achieved its sixth consecutive quarter of year-over-year volume growth, with broad gains across regions and continued momentum from our globalize and innovate strategies. Personal Care generated another quarter of strong performance, with eight percent sales growth, including double-digit growth in biofunctional actives, microbial protection and hair care, and high-single-digit growth in skin care. Specialty Additives delivered nine percent sales growth in coatings and fourteen percent sales growth in performance specialties, reflecting share gains across all regions. These gains were offset by soft end-market demand in energy and resources and lower construction volumes resulting from deliberate portfolio actions.”

"Our globalize and innovate strategies exceeded their full-year targets, driven by deep customer engagement and successful commercialization," said Guillermo Novo, chair and chief executive officer, Ashland. “Despite raw material and freight volatility, our teams executed well, with pricing actions recovering higher raw material costs. We have completed the critical investments needed to support improved productivity at our plants. We also generated healthy cash flow, further strengthening our financial flexibility as we enter fiscal 2027."

Novo continued, "Our priorities are clear: improve operating performance, drive productivity across our network, maintain pricing discipline, build on our commercial momentum and continue to scale our globalize and innovate initiatives. The strategic foundations are in place, and our focus is on execution to deliver improved profitability and long-term value creation."

Fourth-quarter sales were $498 million, up four percent from $478 million in the prior-year quarter. Sales volumes increased three percent, led by Pharma, Personal Care, Coatings and Performance Specialties. Pricing increased two percent, covering raw material cost inflation across all business units. Foreign currency movements reduced sales by approximately $3 million, or one percent.

Net loss was $16 million, compared with net income of $32 million in the prior-year quarter. Loss from continuing operations was $17 million, or ($0.36) per diluted share, compared with income from continuing operations of $33 million, or $0.73 per diluted share, in the prior-year quarter. Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense was $52 million, up from $50 million, or $1.12 per diluted share versus $1.08 in the prior-year quarter. Adjusted Operating Income was $77 million, up from $71 million in the prior-year quarter. Adjusted EBITDA was $121 million, up two percent from $119 million, and Adjusted EBITDA margin was 24.3 percent compared with 24.9 percent in the prior-year quarter. Double-digit Adjusted EBITDA growth in Life Sciences, Personal Care and Intermediates was partially offset by lower earnings in Specialty Additives, reflecting an unfavorable absorption impact, and higher unallocated corporate expenses. Foreign currency movements reduced Adjusted EBITDA by approximately $2 million.

Average diluted shares outstanding were 46 million in the fourth quarter, unchanged from the prior-year quarter.

Cash flows provided by operating activities were $90 million, up from $40 million in the prior-year quarter, driven primarily by lower working capital. Ongoing Free Cash Flow totaled $74 million versus $52 million in the prior-year quarter, representing Ongoing Free Cash Flow conversion of 61 percent versus 44 percent in the prior-year quarter, primarily reflecting the year-over-year reduction in working capital.

Reportable Segment Performance To aid in the understanding of Ashland’s ongoing business performance, the results of Ashland’s reportable segments are described below on an adjusted basis. In addition, EBITDA and Adjusted EBITDA are reconciled to operating income in Table 4. Free Cash Flow, Ongoing Free Cash Flow and Adjusted Operating Income are reconciled in Table 6 and Adjusted Income from Continuing Operations, Adjusted Diluted Earnings Per Share and Adjusted Diluted Earnings Per Share Excluding Intangible Amortization Expense are reconciled in Table 7 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the “Use of Non-GAAP Measures” section that further describes these adjustments below.

Life Sciences Sales for the Life Sciences segment totaled $180 million in the fourth quarter, an increase of four percent compared with the prior-year quarter. Performance was driven by higher volumes, led by broad pharma growth across all major regions and technology platforms, including VP&D, cellulosics, injectables and film coatings. Pharma sales increased approximately six percent, representing the sixth consecutive quarter of year-over-year volume growth, supported by continued momentum from Ashland's globalize and innovate strategies. Nutrition sales declined slightly due to lower volumes. Prices increased approximately one percent compared with the prior year and covered cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.

Adjusted Operating Income for the quarter was $50 million, up from $41 million in the prior-year quarter. Adjusted EBITDA totaled $64 million, an increase of 16 percent compared with $55 million in the prior-year quarter, and Adjusted EBITDA margin increased 380 basis points to 35.6 percent, the highest quarterly margin in the segment's history. The year-over-year increase was driven primarily by higher volumes, favorable product mix, pricing and cost performance. Foreign currency movements reduced Adjusted EBITDA by approximately $1 million during the quarter.

Personal Care Personal Care sales in the fourth quarter were $163 million, an increase of eight percent compared with $151 million in the prior-year quarter. Performance reflected broad-based gains across the portfolio, including double-digit sales growth in biofunctional actives and microbial protection. Care Ingredients delivered strong results, led by double-digit growth in hair care and high-single-digit growth in skin care, while oral care and household sales declined by a low-single-digit percentage in aggregate. Performance was also strong across regions, with year-over-year sales growth in North America, Europe, China, Latin America and Rest of Asia. Prices increased modestly compared with the prior year and covered raw material cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.

Adjusted Operating Income was $35 million, up 25 percent from $28 million in the prior-year quarter. Adjusted EBITDA was $49 million, up 14 percent from $43 million in the prior-year quarter, and Adjusted EBITDA margin increased 160 basis points to 30.1 percent. The year-over-year increase was driven primarily by higher sales volumes, favorable product mix, pricing and cost performance. Foreign currency movements had a negligible impact on Adjusted EBITDA.

Specialty Additives Specialty Additives sales were $131 million in the fourth quarter, in line with the prior-year quarter. Coatings sales increased nine percent and Performance Specialties sales increased fourteen percent, reflecting favorable volumes, pricing and share gains across all regions, including a third consecutive quarter of year-over-year sales growth in China. These gains were offset by soft end-market demand in Energy and Resources and lower Construction volumes resulting from deliberate portfolio actions to prioritize higher-value applications. Prices increased approximately five percent compared with the prior-year quarter, covering raw material cost inflation. Foreign currency movements reduced segment sales by approximately $1 million.

Adjusted Operating Income was $5 million, compared with $12 million in the prior-year quarter, and Adjusted EBITDA was $20 million, down 31 percent from $29 million in the prior-year quarter. The year-over-year decline primarily reflected lower Hopewell productivity and related unfavorable absorption. Key productivity investments are now complete, with the focus on execution to increase production. Favorable price and mix partially offset these pressures. Foreign currency movements reduced Adjusted EBITDA by approximately $1 million.

Intermediates Intermediates sales totaled $33 million in the fourth quarter, in line with the prior-year quarter. Merchant sales increased four percent to $24 million, offset by a $1 million decline in captive sales to $9 million. Favorable merchant mix, including higher NMP sales, and pricing more than offset lower merchant BDO volumes. Pricing increased approximately five percent compared with the prior-year quarter and covered raw material inflation. Foreign currency movements had a negligible impact on segment sales.

Adjusted Operating Income was $4 million, compared with $2 million in the prior-year quarter. Adjusted EBITDA was $6 million, up 20 percent from $5 million in the prior-year quarter, and Adjusted EBITDA margin increased 300 basis points to 18.2 percent. The year-over-year improvement was driven primarily by favorable merchant mix, pricing and cost performance, partially offset by lower volumes. Foreign currency movements had a negligible impact on Adjusted EBITDA during the quarter.

Unallocated & Other Unallocated and other expense was $44 million, compared with $11 million in the prior-year quarter. The year-over-year increase primarily reflected higher restructuring charges and a cumulative translation adjustment associated with the liquidation of Ashland’s Argentine entity. Adjusted unallocated and other EBITDA expense was $18 million compared with $13 million in the prior-year quarter, primarily reflecting higher incentive and stock-based compensation expense.

Fiscal Year 2026 Results Summary Sales were $1.863 billion, up two percent from $1.824 billion in the prior year. Excluding the impact of the previously announced Avoca divestiture, organic sales increased three percent. Commercial momentum strengthened throughout the year, with second-half sales increasing approximately six percent year over year. Life Sciences benefited from sustained pharma growth, Personal Care delivered broad-based growth across its higher-value businesses, and within Specialty Additives, Coatings and Performance Specialties gained momentum as the year progressed. For the full year, volumes contributed approximately two percent to sales, pricing had a negligible impact, and foreign currency contributed approximately one percent. Pricing strengthened in the second half as actions were taken to offset cost inflation.

Net income was $4 million, compared with a net loss of $845 million in the prior year. Income from continuing operations was $25 million, or $0.55 per diluted share, compared with a loss from continuing operations of $822 million, or ($17.74) per diluted share, in fiscal 2025. The significant year-over-year improvement in reported results primarily reflected the absence of the $706 million non-cash goodwill impairment and $175 million Avoca-related impairment and sale adjustment recognized in fiscal 2025. Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense was $153 million, or $3.31 per diluted share, compared with $157 million, or $3.38 per diluted share, in the prior year.

Adjusted EBITDA was $385 million, compared with $401 million in fiscal 2025, including a $1 million year-over-year impact from the Avoca divestiture. Life Sciences and Personal Care delivered Adjusted EBITDA and margin growth, supported by resilient demand, favorable mix and strong execution. Within Specialty Additives, strong commercial performance in Coatings and Performance Specialties was more than offset by lower Hopewell productivity and the related unfavorable absorption impact. Intermediates profitability improved as the year progressed, supported by favorable merchant mix, pricing and cost performance. Overall Adjusted EBITDA margin was 20.7 percent, compared with 22.0 percent in fiscal 2025.

Cash flow from operating activities was $385 million, compared with $134 million in the prior year. Ongoing Free Cash Flow was $232 million, compared with $127 million in fiscal 2025. The year-over-year improvement primarily reflected lower working capital, driven by reduced inventory, as well as lower capital expenditures. Ashland ended fiscal 2026 with approximately $480 million of cash, $976 million of total liquidity and net debt of $891 million. Net leverage of 2.3x was within the company's long-term target range, providing significant financial flexibility entering fiscal 2027.

Throughout fiscal 2026, Ashland continued to advance its Execute, Globalize and Innovate priorities, strengthening its operating foundation while expanding opportunities for profitable growth. Execute initiatives delivered benefits across multiple pillars during the year, but Hopewell HEC productivity was below expectations. Globalize generated approximately $26 million of incremental sales, exceeding its fiscal 2026 target of $20 million. Innovate generated approximately $26 million of incremental sales, exceeding its fiscal 2026 target of $15 million. The company continued to advance its longer-term innovation portfolio toward customer validation, commercial launch and scaling. These initiatives position Ashland to deliver improved profitability, cash generation and sustainable long-term growth.

Financial Outlook

Ashland is issuing the following guidance for fiscal 2027, reflecting its current expectations for market conditions, business performance and continued execution of its strategic priorities.

Full-year fiscal 2027 guidance

  • Sales:$1,905 million to $1,975 million, reflecting growth of approximately two to six percent over the prior year

  • Adjusted EBITDA:$405 million to $435 million

  • **Ongoing Free Cash Flow Conversion:**greater than 40 percent of Adjusted EBITDA, reflecting a modest increase in inventory and capital expenditures of up to approximately $140 million

Key planning assumptions

  • **Demand environment:**the outlook reflects a measured assessment of global demand conditions across Ashland's end markets. Demand in Life Sciences and Personal Care is expected to remain resilient, supported by continued pharma momentum and growth across higher-value Personal Care applications. Within Specialty Additives, Coatings and Performance Specialties are expected to build on recent commercial momentum. Intermediates is expected to benefit from new customer volumes in energy storage.

  • Commercial execution: Ashland expects continued execution of its globalize and innovate initiatives to support profitable growth. The company remains focused on expanding adoption of higher-value solutions and scaling commercial opportunities across its key end markets.

  • **Pricing and input costs:**raw material and freight costs are expected to remain volatile during fiscal 2027, with pricing actions expected to offset anticipated inflation.

  • **Operational performance:**the outlook incorporates expected year-over-year benefits from non-recurring events and improved manufacturing productivity. Improving plant operations remains a key priority for fiscal 2027.

  • **Foreign currency:**based on recent spot rates, the outlook reflects a stronger U.S. dollar, resulting in estimated headwinds of approximately $20-$25 million to sales and $7-$10 million to Adjusted EBITDA.

Fiscal 2027 strategic priority targets

  • **Execute:**deliver approximately $10 million in net incremental productivity and manufacturing optimization benefits.

  • **Globalize:**generate approximately $20 million in incremental sales by scaling biofunctional actives, microbial protection, injectables and tablet coatings through geographic expansion and increased customer penetration.

  • **Innovate:**generate $45 million in incremental innovation-driven sales through the commercialization of new technologies, scaling of recently launched solutions and increased customer adoption.

"Our performance improved as the year progressed, reflecting the strength of our strategy and the commitment of our teams," concluded Novo. "Although the external markets remain challenging, we have a resilient portfolio with all businesses well positioned to focus on the factors within our control and deliver profitable growth.”

Conference Call Webcast The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, November 4, 2026. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.

To access the call by phone, please go to this registration link and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

Following the live event, an archived version of the webcast and supporting materials will be available for 12 months at http://investor.ashland.com.

Use of Non-GAAP Measures Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes, and certain other charges that are highly variable from year to year, EBITDA, Adjusted EBITDA, EBITDA Margin and Adjusted EBITDA Margin provide Ashland’s investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin, and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, Adjusted EBITDA, EBITDA Margin and Adjusted EBITDA Margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, Adjusted EBITDA, EBITDA Margin, and Adjusted EBITDA Margin provide disclosure on the same basis as that used by Ashland’s management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland’s historical operating performance and its business units, and provide continuity to investors for comparability purposes. EBITDA Margin and Adjusted EBITDA Margin are defined as EBITDA and Adjusted EBITDA divided by sales for the corresponding period.

Key items, which are set forth on Table 7 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to reflect Ashland’s underlying business performance and trends most accurately. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor’s ability to compare financial performance between reporting periods.

Tax-specific key items, which are set forth on Table 7 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland’s underlying business performance and trends.

The Free Cash Flow metrics enable Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, Free Cash Flow and Ongoing Free Cash Flow include the impact of capital expenditures from continuing operations and other significant items impacting Free Cash Flow, providing a more complete picture of current and future cash generation. Free Cash Flow, Ongoing Free Cash Flow, and Ongoing Free Cash Flow Conversion are non-GAAP liquidity measures that Ashland believes provide useful information to management and investors about Ashland’s ability to convert Adjusted EBITDA to ongoing Free Cash Flow. These liquidity measures are used regularly by Ashland’s stakeholders and industry peers to measure the efficiency at providing cash from regular business activity. Free Cash Flow, Ongoing Free Cash Flow, and Free Cash Flow Conversion have certain limitations, including that they do not reflect adjustments for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Adjusted Diluted Earnings Per Share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing earnings and diluted earnings per share metrics that exclude the effect of the identified key items and tax specific key items.

The Adjusted Diluted Earnings Per Share Excluding Intangibles Amortization Expense metric enables Ashland to demonstrate the impact of non-cash intangibles amortization expense on earnings per share, in addition to key items previously mentioned. Ashland’s management believes this presentation is helpful to illustrate how previous acquisitions impact applicable period results.

Ashland does not quantitatively reconcile our guidance ranges for our non-GAAP measures to their most comparable GAAP measures in the Financial Outlook section of this news release. The guidance ranges for GAAP and non-GAAP financial measures reflect Ashland’s assessment of potential sources of variability in financial results and are informed by evaluation of multiple scenarios, many of which have interactive effects across several financial statement line items. Providing guidance for individual reconciling items between our non-GAAP financial measures and the comparable GAAP measures would imply a degree of precision and certainty in those reconciling items that is not a consistent reflection of our scenario-based process to prepare our guidance ranges. To the extent that a material change affecting the individual reconciling items between the company’s forward-looking non-GAAP and comparable GAAP financial measures is anticipated, the company has provided qualitative commentary in the Financial Outlook section of this news release for your consideration. However, as the impact of such factors cannot be predicted with a reasonable degree of certainty or precision, a quantitative reconciliation is not available without unreasonable effort.

About Ashland Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceuticals. Approximately 2,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.

Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the U.S. Securities and Exchange Commission (“SEC”), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance, financial, operating cash flow and liquidity, as well as the economy and other future events or circumstances. These statements include, but are not limited to, expectations regarding the fiscal 2027 financial outlook and the key planning assumptions underlying that outlook, expected improvements in plant reliability and productivity, including the pace of improvement in Hopewell output and the timing of a Specialty Additives margin recovery; anticipated productivity and manufacturing optimization benefits, including those from the HEC and VP&D networks and the small plant consolidation initiative; Ashland’s fiscal 2027 Execute, Globalize and Innovate targets and the advancement of its innovation portfolio and Technology Platforms; Ashland’s commercial momentum and competitive positioning; Ashland’s cash generation and financial flexibility; and Ashland’s ability to deliver improved profitability and create long-term value.

Ashland’s expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: Ashland’s aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, and any unexpected costs and liabilities associated with such acquisitions, and goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland’s products; risks inherent in operating a global business, including tariffs and other trade policies, and geopolitical instability and armed conflict; economic downturns and disruptions in the financial markets; Ashland’s substantial indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward pressures on prices and margins; the ability to attract and retain key employees, including across foreign jurisdictions where employment laws and business and cultural practices may differ, and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland’s information technology systems and networks, malicious cyberattacks, the inadvertent or accidental disclosure or loss of proprietary or sensitive information, and cyber risks related to Ashland’s external service providers and other third parties; risks related to Ashland’s use of artificial intelligence, including the potential for flawed or unreliable outputs, and the complexities and uncertainties in the legal and regulatory landscapes; Ashland’s ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; changes in taxation or adverse tax rulings; and, without limitation, risks and uncertainties affecting Ashland that are described in Ashland’s most recent Annual Report on Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland’s website at http://investor.ashland.com or on the SEC’s website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.

1Financial results are preliminary until Ashland’s Form 10-K is filed with the U.S. Securities and Exchange Commission.

2The Ongoing Free Cash Flow metric excludes the impact of inflows and outflows from U.S. and Foreign Accounts Receivable Sales Program and payments related to restructuring and environmental and litigation-related matters in both the current-year and prior-year periods.

™ Trademark, Ashland or its subsidiaries, registered in various countries.

October 27, 2026

WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2026 earnings release at approximately 5 p.m. ET on Tuesday, November 3, 2026. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, November 4. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.

Among those participating in the webcast presentation will be:

  • Guillermo Novo, chair, and chief executive officer

  • William Whitaker, senior vice president, and chief financial officer

  • Dago Caceres, senior vice president, general manager, specialty additives

  • Alessandra Faccin, senior vice president, general manager, life sciences and intermediates

  • Jim Minicucci, senior vice president, general manager, personal care

  • Sandy Klugman, director, investor relations

To access the call by phone, please go to this registration link and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

The webcast and supporting materials will be accessible through the Investor Relations section of Ashland's website at http://investor.ashland.com. Following the live event, an archived version of the webcast and supporting materials will be available on the Ashland website for 12 months.

October 8, 2026

PDF Version 89.4 KB

Traceable, ethical, abundant condurango bark extract helps skin self-detox, breathe, fortify and regain positive sensations

WILMINGTON, Del., October 8, 2026 — Ashland Inc. (NYSE: ASH) today announced the launch of forzango™ biofunctional, an active ingredient obtained by supercritical CO2 extraction from traceable, ethically-sourced and abundant condurango bark, created for a generation that no longer separates taking care of physical health from taking care of beauty.

For decades, sweat, sun and physical exertion were viewed as stressors from which skin needed to recover. Today, movement is recognized as one of the most powerful ways to support overall health. A Harvard-led study of more than 147,000 people, published in the British Journal of Sports Medicine in June 2026, links strength training to a lower risk of early death — adding longevity to a list of benefits that already runs from immunity to brain age.

According to Mintel, sport is now a valuable growth space for beauty as consumers align their identity with their active lifestyles — and for Gen Z, radiant skin reads as the visible proof of a well-lived routine including sleep, nutrition, hydration and movement. Self-care and performance have become the same gesture.

"The old assumption was that active living came at your skin's expense. The new one is that they're on the same side," said Eloïse Dewitte, global marketing, Biofunctionals, Ashland. "Our customers are formulating for people who train, commute, travel and go out — often on the same day. What they need isn't skin repair after the fact, it's skin with endurance."

Ashland forzango™ biofunctional was designed as a complete endurance program rather than a single-benefit active, working across four proven axes including:

  • helping the skin self-detox by increasing the toxin-sensing ability of the skin and its own clean-up systems (autophagy processes)

  • empowering the skin respirasome by increasing mitochondrial complex IV under toxic stress

  • fortifying the skin, strengthening antimicrobial defenses and the skin barrier function

  • increasing skin comfort by limiting biological signaling linked to skin discomfort under nervous stress

Clinical results were obtained on a mixed panel of 30 men and women, against placebo — a deliberately unisex protocol for a deliberately unisex claim. After six weeks, fine lines, roughness and signs of oxygenation significantly improved, 80 percent of volunteers agreed their skin felt more comfortable and 60 percent found it looked smoother.

traceable ethical, abundant

Forzango™ biofunctional is obtained by supercritical CO2 extraction from condurango bark (Marsdenia condurango), a vigorous liana that climbs Andean trees to reach the light and thrives at 1,400 to 2,100 meters, adapting to low oxygen levels. Its name comes from condur-angu, "eagle remedy."

The ingredient is the result of a ten-year sourcing program implemented by a trusted partner of Ashland in Colombia and the first foreign initiative to obtain a bioprospection research permit in the country. Traditionally wild-harvested, condurango was domesticated through a dedicated cultivation project in the Valle del Cauca, with seeds and nurseries certified by the Instituto Colombiano Agropecuario. Ten smallholder farmers now grow it under multi-year contracts with technical training, organic-farming practices and fair pricing, under an ABS-compliant benefit-sharing agreement aligned with the 12 criteria of negocios verdes.

"Relieving pressure on a wild resource while creating real economic value for local growers was the only acceptable way to build this supply chain," said Frédéric Faugeroux, general manager, Biofunctionals, Ashland. "It's traceable, ethical and abundant."

formulation-ready across the active routine

Oil-soluble, preservative-free and recommended at one percent use level, forzango™ biofunctional is 100 percent natural origin (ISO 16128), COSMOS-approved, readily biodegradable (OECD 301D), vegan suitable, non-GMO and China-compliant (IECIC listed). Ashland recommends use across active consumer products including pre-workout face primers and sport SPF sticks, cooling recovery mists and gel-creams, anti-friction body balms, and daily endurance serums, barrier creams and post-shave care.

Available globally, the product will be showcased at tradeshows including In Cosmetics Asia (Thailand), SEPAWA (Germany), Cosmetorium (Spain), SCS Formulate (UK), Making Cosmetics (Italy) and more. Visit ashland.com/forzango to learn more.

Prompts

Ashland Inc. (ticker ASH), listed in United States.

Company History

Date Change Detail
Aug 1, 2022 Renamed ASHLAND GLOBAL HOLDINGS INC → ASHLAND INC.
— Predecessor Predecessor Ashland Inc. (CIK 1305014) filed under its own registration; its figures are on its own company page, not shown here.
— Predecessor Predecessor Ashland Inc (CIK 7694) filed under its own registration; its figures are on its own company page, not shown here.

ETFs Holding Ashland Inc.

ETF Weight in ETF Shares Market value As of
AVUV 0.32% 1,344,236 $ 101.584M Nov 16, 2026
DFSV 0.24% 860,708 $ 64.785M Nov 12, 2026
AVSC 0.22% 91,365 $ 6.904M Nov 16, 2026
GVLU 0.18% 6,300 $ 476.091K Nov 17, 2026
DFAT 0.13% 548,719 $ 41.302M Nov 12, 2026
RESM 0.12% 67 $ 4,414.63 Jun 30, 2026
DFAS 0.08% 337,886 $ 25.433M Nov 12, 2026
CDX short -0.07% -2,397.5773 $ -177.78K Nov 17, 2026
JMEE 0.06% 24,725 $ 1.833M Nov 17, 2026
DXUV 0.03% 27,433 $ 2.065M Nov 12, 2026
VFMF 0.03% 3,410 $ 250.055K Aug 31, 2026
MSSM 0.02% 2,230 $ 163.526K Aug 31, 2026
AVSU 0.02% 1,019 $ 77.006K Nov 16, 2026
SFGV 0.02% 2,819 $ 210K Nov 18, 2026
DFSU 0.02% 5,804 $ 436.867K Nov 12, 2026
DFAC 0.02% 199,239 $ 14.997M Nov 12, 2026
DFUV 0.01% 27,904 $ 2.1M Nov 12, 2026
DCOR 0.01% 62,353 $ 4.693M Nov 12, 2026
AVUS 0.01% 23,492 $ 1.775M Nov 16, 2026
DFAU 0.01% 11,774 $ 886.229K Nov 12, 2026
DFUS 0.00% 13,542 $ 1.019M Nov 12, 2026
MSLC 0.00% 1,634 $ 119.821K Aug 31, 2026
EBI 0.00% 12 $ 879.96 Aug 31, 2026
NTRL short 0.00% -821 $ 0.00 Nov 16, 2026